BRPI0411982A - glicano de aperfeiçoamento de terapia - Google Patents

glicano de aperfeiçoamento de terapia

Info

Publication number
BRPI0411982A
BRPI0411982A BRPI0411982-7A BRPI0411982A BRPI0411982A BR PI0411982 A BRPI0411982 A BR PI0411982A BR PI0411982 A BRPI0411982 A BR PI0411982A BR PI0411982 A BRPI0411982 A BR PI0411982A
Authority
BR
Brazil
Prior art keywords
glycan
composition
relates
cells
subject
Prior art date
Application number
BRPI0411982-7A
Other languages
English (en)
Inventor
Nai-Kong V Cheung
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of BRPI0411982A publication Critical patent/BRPI0411982A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"GLICANO DE APERFEIçOAMENTO DE TERAPIA". A presente invenção refere-se a um processo para introdução de substâncias em células compreendendo contato de uma composição compreendendo beta-glicano administrado oralmente com as ditas células. Esta invenção também refere-se a um processo para introdução de substâncias em um sujeito compreendendo administração ao sujeito de uma quantidade eficaz das composições acima. A substância que pode ser liberada oralmente inclui mas não é limitada a peptídeos, proteínas, RNAs, DNAs, agentes quimioterapêuticos, agentes biologicamente ativos, plasmídeos, e outros compostos e moléculas pequenas. Finalmente, esta invenção refere-se a uma composição compreendendo beta-glicano administrado oralmente capaz de aperfeiçoar eficácia de IgM e diferentes usos da dita composição.
BRPI0411982-7A 2003-07-16 2004-07-16 glicano de aperfeiçoamento de terapia BRPI0411982A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/621,027 US7507724B2 (en) 2001-01-16 2003-07-16 Therapy-enhancing glucan
PCT/US2004/023099 WO2005018544A2 (en) 2003-07-16 2004-07-16 Therapy-enhancing glucan

Publications (1)

Publication Number Publication Date
BRPI0411982A true BRPI0411982A (pt) 2006-08-29

Family

ID=34216281

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411982-7A BRPI0411982A (pt) 2003-07-16 2004-07-16 glicano de aperfeiçoamento de terapia

Country Status (9)

Country Link
US (11) US7507724B2 (pt)
EP (1) EP1651676B1 (pt)
JP (1) JP4903041B2 (pt)
KR (1) KR101197327B1 (pt)
CN (1) CN1823092B (pt)
AU (1) AU2004266138C1 (pt)
BR (1) BRPI0411982A (pt)
CA (1) CA2536632C (pt)
WO (1) WO2005018544A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2004014320A2 (en) * 2002-08-13 2004-02-19 Biopolymer Engineering, Inc. Methods of using beta glucan as a radioprotective agent
US8883760B2 (en) * 2002-09-04 2014-11-11 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
EP1736773B1 (en) * 2004-04-16 2014-07-02 Ajinomoto Co., Inc. Assaying potency of peripheral mononuclear blood cell to bind to polysaccharide
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
AU2005284727A1 (en) 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
CN103285392A (zh) * 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
US20070059310A1 (en) * 2005-05-03 2007-03-15 Karel Steven J Therapeutic combination compositions and methods of using same
MX2007013725A (es) 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
ATE526991T1 (de) * 2005-10-24 2011-10-15 Univ Massachusetts Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
EP1984004A4 (en) * 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer THE THERAPY REINFORCING GLUCAN
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
ES2397186T3 (es) * 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
WO2008130719A1 (en) * 2007-04-24 2008-10-30 University Of Louisville Therapeutic beta-glucan combinations
EP2222283A2 (en) 2007-10-29 2010-09-01 University of Massachusetts Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna)
US20110053855A1 (en) * 2008-02-19 2011-03-03 Novogen Research Pty Ltd. Ex vivo cell stimulation
NO2700405T3 (pt) 2008-05-29 2018-09-01
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
EP3363462A1 (en) 2012-04-30 2018-08-22 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy
CA2920310A1 (en) * 2013-08-06 2015-02-12 Commonwealth Scientific And Industrial Research Organisation Wheat having high levels of beta-glucan
WO2016007876A1 (en) * 2014-07-10 2016-01-14 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
US9963509B2 (en) 2014-12-23 2018-05-08 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
US10865245B2 (en) 2014-12-23 2020-12-15 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
MX2019011664A (es) * 2017-03-28 2019-11-18 Cargill Inc Suspensiones de betaglucanos facilmente dispersables en agua.
US12544344B2 (en) 2017-04-19 2026-02-10 Phio Pharmaceuticals Corp. Topical delivery of nucleic acid compounds
US10946038B2 (en) 2017-08-09 2021-03-16 Case Western Reserve University Cancer treatment using beta-(1-3)-(1-4)-glucan
JP7438131B2 (ja) * 2018-04-24 2024-02-26 メモリアル スローン－ケタリング キャンサー センター 経口酵母ベータグルカンを用いる低免疫原性抗原特異的ワクチンの免疫原性強化方法
EP3858362A1 (en) 2020-01-29 2021-08-04 Pleuran, s.r.o. Beta-glucan for use in enhancement of anti-tumor immunity in remission
US11572420B1 (en) * 2021-07-30 2023-02-07 Tissue repair ltd Isolated biological polysaccharide compound, methods of use and methods of manufacture thereof
US12433915B2 (en) 2022-11-23 2025-10-07 Jjr&D, Llc Cancer cytotoxic exosome formulations and methods for use in treating cancer
CN116004408A (zh) * 2022-12-29 2023-04-25 浙江大学杭州国际科创中心 一种乙酸耐受酵母突变体及其制备方法和应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975553A (en) * 1965-03-08 1976-08-17 Henri Griffon Deproteination of yeast cells
US3987166A (en) 1970-05-13 1976-10-19 Kaken Kagaku Kabushiki Kaisha Treatment of tumors with glucan compositions in mice and rats
FR2447193A1 (fr) * 1979-01-25 1980-08-22 Unicler Utilisation de pichia ou d'extraits de pichia, comme medicament.
US4251519A (en) * 1979-07-30 1981-02-17 Anheuser-Busch, Incorporated Process for the prevention and reduction of elevated blood cholesterol and triglycerides levels
FR2477416A1 (fr) * 1980-03-10 1981-09-11 Unicler Utilisation de hansenula ou d'extraits de hansenula, comme medicament
DE3019614A1 (de) 1980-05-22 1981-12-03 Sankyo Co., Ltd., Tokyo Hydrolysiertes polysaccharid
JPS6346436B2 (pt) 1980-08-14 1988-09-14 Fujitsu Ltd
US4454289A (en) * 1981-03-06 1984-06-12 Takara Shuzo Co., Ltd. Polysaccharides having anticarcinogenic activity and method for producing same
US4477432A (en) * 1981-05-01 1984-10-16 Cutter Laboratories, Inc. Oral immune globulin
US4731245A (en) * 1983-12-29 1988-03-15 Kitasato Kenkyusho Vaccine, antigen and antibody for treating microorganisms of the MCLS-type streptococcus sanguis
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5250436A (en) * 1984-11-28 1993-10-05 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5037972A (en) * 1984-11-28 1991-08-06 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4992540A (en) * 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
CA1340080C (en) * 1985-03-11 1998-10-13 Dorothee Herlyn Human tumor therapy
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
JPS62252730A (ja) 1986-01-16 1987-11-04 Takeda Chem Ind Ltd 抗腫瘍剤
ES2023680B3 (es) * 1987-03-03 1992-02-01 Centre De Rech En Physique Des Plasmas Girotron de alto rendimiento para obtencion de ondas electromagneticas milimetricas o submilimetricas
JPS63307825A (ja) 1987-06-08 1988-12-15 Nippon Beet Sugar Mfg Co Ltd 抗腫瘍剤及びその製法
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5189028A (en) 1989-02-20 1993-02-23 Taito Co., Ltd. Composition and method to enhance the efficacy of a fish vaccine and to stimulate the immune system of fish
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
JPH05503952A (ja) * 1989-09-08 1993-06-24 アルファ　ベータ　テクノロジー，インコーポレイティッド 可溶性グルカン類の製造方法
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
EP0491829B1 (en) 1989-09-08 1997-06-04 Alpha Beta Technology, Inc. Composition for immune system activation
US6020324A (en) * 1989-10-20 2000-02-01 The Collaborative Group, Ltd. Glucan dietary additives
US6143731A (en) * 1989-10-20 2000-11-07 The Collaborative Group, Ltd. Glucan dietary additives
US5223491A (en) 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
JP2911554B2 (ja) 1990-06-25 1999-06-23 台糖株式会社 抗ウィルス剤
DE4107154A1 (de) * 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
JPH05805A (ja) 1991-06-20 1993-01-08 Sumitomo Electric Ind Ltd ゾルゲル法による薄膜の作製方法
ZA935649B (en) * 1992-08-05 1994-03-07 Bioglucans L P Method for preparing soluble glucans
IT1256035B (it) * 1992-08-10 1995-11-21 Consiglio Nazionale Ricerche Glucani ad attivita' immunostimolante
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
US5519009A (en) * 1993-10-01 1996-05-21 Donzis; Byron A. Solubilized yeast glucan
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5576015A (en) * 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
US20030180254A1 (en) * 1995-05-26 2003-09-25 The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US6117850A (en) * 1995-08-28 2000-09-12 The Collaborative Group, Ltd. Mobilization of peripheral blood precursor cells by β(1,3)-glucan
US5614242A (en) * 1995-09-27 1997-03-25 Barkley Seed, Inc. Food ingredients derived from viscous barley grain and the process of making
JP2859843B2 (ja) * 1996-03-08 1999-02-24 株式会社雪国まいたけ マイタケから抽出した抗腫瘍物質
US5951976A (en) 1996-03-28 1999-09-14 Whitenead Institute For Biomedical Research Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
JPH09304714A (ja) * 1996-05-10 1997-11-28 Canon Inc 走査光学装置
WO1998039013A1 (en) 1997-03-04 1998-09-11 Peregrine Pharmaceutical, Inc. Composition and method for treating cancer and immunological disorders resulting in chronic conditions
US6096310A (en) * 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
US5980918A (en) 1997-10-24 1999-11-09 Brennen Medical, Inc. β-D-glucan topical composition
ATE364395T1 (de) 1998-04-10 2007-07-15 Andrew Lees Konjugat-impfstoffe zur vorbeugung der zahnkaries
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US6369216B1 (en) * 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
US6143883A (en) * 1998-12-31 2000-11-07 Marlyn Nutraceuticals, Inc. Water-soluble low molecular weight beta-glucans for modulating immunological responses in mammalian system
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US7927612B2 (en) 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
US7297330B2 (en) 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
US20020009463A1 (en) 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
IT1318403B1 (it) 2000-03-17 2003-08-25 Cooperativa Ct Ricerche Poly T Esteri polisaccaridici di n-derivati di acido glutammico.
FR2808687B1 (fr) 2000-04-27 2003-12-05 Goemar Lab Sa Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
EP1322383B9 (en) * 2000-10-02 2006-09-06 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
AU2002243267A1 (en) 2000-10-27 2002-06-24 Mannatech, Inc. Dietary supplement compositions
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
EP1357919B1 (en) 2001-01-16 2017-04-05 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
KR20090057480A (ko) * 2001-04-27 2009-06-05 아지노모토 가부시키가이샤 면역강화제
CN1394867A (zh) 2001-07-06 2003-02-05 中国科学院生态环境研究中心 可作药物的寡糖和其制备方法及含该寡糖的药物组合物
KR20050043736A (ko) 2001-11-06 2005-05-11 오리엔트 캔서 세라피 컴퍼니 리미티드 항암 조성물
CN1596116A (zh) 2001-11-06 2005-03-16 东方癌症治疗株式会社 抗癌组合物
JP2005513140A (ja) 2001-12-11 2005-05-12 セアプロ インク 穀類βグルカン組成物、その調製方法及び使用
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
WO2004014320A2 (en) 2002-08-13 2004-02-19 Biopolymer Engineering, Inc. Methods of using beta glucan as a radioprotective agent
US20060165700A1 (en) 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
US8883760B2 (en) 2002-09-04 2014-11-11 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
US20050065114A1 (en) 2003-09-23 2005-03-24 Jean-Claude Yvin Therapeutical treatment with oligo-beta- (1,3) -glucans, drugs used in said treatment
US7671040B2 (en) 2003-09-23 2010-03-02 Laboratoires Goemar S.A. Chemotherapeutic antineoplastic treatment
US7070778B2 (en) 2003-10-30 2006-07-04 Laboratoire Goemar Sa Therapeutical combination against cancer
CN1964722A (zh) 2004-05-10 2007-05-16 生物聚合物工程有限公司 与抗生素、疫苗和病毒单克隆抗体组合的全葡聚糖颗粒
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
CN103285392A (zh) 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
US20070059310A1 (en) 2005-05-03 2007-03-15 Karel Steven J Therapeutic combination compositions and methods of using same
KR100648194B1 (ko) * 2005-07-27 2006-11-23 삼성전자주식회사 반도체 장치의 제조 방법
US20070134259A1 (en) 2005-11-21 2007-06-14 David Bundle Methods and compositions for pharmacologially controlled targeted immunotherapy
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
EP1984004A4 (en) 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer THE THERAPY REINFORCING GLUCAN
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
CN101072482A (zh) * 2006-05-12 2007-11-14 富准精密工业(深圳)有限公司 散热装置及使用该散热装置的散热系统

Also Published As

Publication number Publication date
US20080193456A1 (en) 2008-08-14
AU2004266138C1 (en) 2009-10-22
WO2005018544A8 (en) 2005-11-10
US20130183295A1 (en) 2013-07-18
US20170232099A1 (en) 2017-08-17
US20130230535A1 (en) 2013-09-05
WO2005018544A3 (en) 2005-06-09
KR101197327B1 (ko) 2012-11-05
CN1823092A (zh) 2006-08-23
US20110195071A1 (en) 2011-08-11
KR20060112708A (ko) 2006-11-01
US20060020128A1 (en) 2006-01-26
US20160166600A1 (en) 2016-06-16
US20060188506A1 (en) 2006-08-24
AU2004266138B2 (en) 2009-02-19
US10307479B2 (en) 2019-06-04
AU2004266138A1 (en) 2005-03-03
US9211304B2 (en) 2015-12-15
US20040116379A1 (en) 2004-06-17
US7462607B2 (en) 2008-12-09
US9480700B2 (en) 2016-11-01
US8791252B2 (en) 2014-07-29
JP4903041B2 (ja) 2012-03-21
JP2007531700A (ja) 2007-11-08
US20140335100A1 (en) 2014-11-13
CN1823092B (zh) 2012-10-17
US20100216743A1 (en) 2010-08-26
EP1651676A2 (en) 2006-05-03
CA2536632A1 (en) 2005-03-03
US7507724B2 (en) 2009-03-24
EP1651676B1 (en) 2018-03-14
US8633170B2 (en) 2014-01-21
EP1651676A4 (en) 2010-01-13
CA2536632C (en) 2011-09-20
WO2005018544A2 (en) 2005-03-03
US7704973B2 (en) 2010-04-27

Similar Documents

Publication Publication Date Title
BRPI0411982A (pt) glicano de aperfeiçoamento de terapia
ES2836184T3 (es) Formulaciones tópicas de co-enzima Q10 y tratamiento de heridas
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
US9050293B2 (en) Small molecule solubilization system
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
BRPI0410306A (pt) métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
BRPI0416260A (pt) método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica
BRPI0406605B8 (pt) conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
BRPI0413889A (pt) formulação lipossÈmica farmacêutica
BR0109983A (pt) Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
CN1270725C (zh) 无机亚硝酸盐和有机酸联合用作局部抗病毒组合物
BRPI0618918B8 (pt) uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
DE60023748D1 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
BR0111257A (pt) Formulação, e, uso de uma formulação
CN1429105A (zh) 含有作为活性成分的辅酶q的皮肤组合物
AR008387A1 (es) Nuevas 5-fenoxialquil-tiazolidin-2,4-dionas, procedimientos para obtenerlas, nuevos compuestos intermedios de estos procedimientos ycomposiciones farmaceuticas que contienen las nuevas 5-fenoxialquil-tiazolidin- 2,4-dionas
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
BRPI0311511A8 (pt) "preparações farmacêuticas líquidas, e sua aplicação".
BR0012610A (pt) Novo derivado de difenilpiperidina
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BR9813514A (pt) Agente para tratamento de fibras queratìnicas
BR0312814A (pt) Levamisol / avermectinas ou similares em solvente de pirrolidona

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2471 DE 15-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.